Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in SLE-Associated PAH
NCT05828147Phase 4Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in pulmonary arterial hypertension (PAH), systemic lupus erythematosus (SLE), sponsored by Chinese SLE Treatment And Research Group. Started May 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
pulmonary arterial hypertension (PAH)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05828147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828147.